Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff

Wall Street analysts rushed to Celldex’s defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva’s research chief accepted a new job.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Friday 20 November →